The European Medicines Agency (EMA) has updated its post-authorization guidance in November 2025, clarifying variation classifications for marketing authorization holders. These revisions address administrative, quality, clinical, and editorial changes, streamlining submissions while ensuring compliance with the EC Variations Guidelines.
Purely administrative updates to manufacturing site names or addresses -without physical relocation- fall under Type IA category E.4, requiring official documentation like GMP certificates but no self-declarations. Multiple sites can be deleted via a single Type IA E.5 variation, provided at least one approved site remains for each function. CEP site changes are handled under Q.III.1 upon new version submission, avoiding parallel E.4 variations.
New finished product manufacturing sites require Type II Q.II.b.1 variations, grouping related extensive changes with precise scopes listing all activities and sites. Active substance site introductions use Q.I.a.1 (e.g., .f for ASMF-supported), with impacts on finished products submitted separately. Pack size additions beyond approved ranges trigger Type IB Q.II.e.6.a.2, while in-range changes are Type IAIN; grouped submissions allow defining new range limits efficiently. Revised CEPs demand Type IA Q.III.1a.2 per version, confirming non-use of omitted revisions if applicable. Non-significant in-process controls qualify for Type IA deletions under specific Q categories, excluding control strategy revisions
Clinical use changes -like indications, posology, or maximum daily doses- necessitate quality dossier reviews for impurities, endotoxins, or excipients, potentially requiring grouped variations. Final non-clinical/clinical study reports submit as Type II C.12 (no PI changes) or relevant C categories otherwise, one per report. Protocols for non-imposed studies can be PAMs unless altering RMP/Annex II, then Type II C.9.c. Therapeutic indication extensions trigger paediatric/orphan checks, even without C.6.a wording changes
Editorial changes -like grammar fixes or reorderings without meaning shifts- integrate into relevant variations, clearly justified in forms; standalone Type IB Q.I/II.z if no upcoming procedures. Working cell banks or reference standards follow approved protocols without variations; otherwise, Type IB/II as needed. Pre-submission queries go to assigned Quality Specialists.
Learn more: Europaema.europa.eu/en/documents/regulatory-procedural-guideline/classification-changes_en.pdf
